Key Takeaway: Precision BioSciences, a clinical stage gene editing company, has announced that it will report its second quarter 2025 results on August 7, 2025. The company utilizes its proprietary ARCUS platform to develop in vivo gene editing therapies aimed at addressing diseases with significant unmet medical needs. This report is anticipated to shed light on their advancements and future plans.
Price reaction · baseline $4.62 (2025-08-01 close) · hit pre-market · 3 other DTIL headline(s) in the window, move may be shared
day 0 close · peak
+4.8%
Market Sentiment Analysis
POSITIVE FACTORS
Precision BioSciences is advancing its gene editing therapies.
The company is addressing diseases with high unmet needs.
The upcoming report may provide insights into their progress.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer
Full Press Release Details
DURHAM, N.C. –(BUSINESS WIRE)–Aug. 4, 2025– Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that it will publish
Frequently Asked Questions
When will Precision BioSciences report its Q2 2025 results?
Precision BioSciences will report its Q2 2025 results on August 7, 2025.
What platform does Precision BioSciences use for gene editing?
Precision BioSciences utilizes its proprietary ARCUS platform for gene editing.
What type of therapies is Precision BioSciences developing?
The company is developing in vivo gene editing therapies for diseases with high unmet needs.